Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

Rupal Ramakrishnan(Moffitt Cancer Center), Deepak Assudani(University of South Florida), Srinivas Nagaraj(University of South Florida), Terri Hunter(University of South Florida), Hyun-Il Cho(University of South Florida), Scott Antonia(University of South Florida), Soner Altiok(University of South Florida), Esteban Celis(University of South Florida), Dmitry I. Gabrilovich(University of South Florida)
Journal of Clinical Investigation
March 16, 2010
Cited by 459Open Access
Full Text

Abstract

Cancer immunotherapy faces a serious challenge because of low clinical efficacy. Recently, a number of clinical studies have reported the serendipitous finding of high rates of objective clinical response when cancer vaccines are combined with chemotherapy in patients with different types of cancers. However, the mechanism of this phenomenon remains unclear. Here, we tested in mice several cancer vaccines and an adoptive T cell transfer approach to cancer immunotherapy in combination with several widely used chemotherapeutic drugs. We found that chemotherapy made tumor cells more susceptible to the cytotoxic effect of CTLs through a dramatic perforin-independent increase in permeability to GrzB released by the CTLs. This effect was mediated via upregulation of mannose-6-phosphate receptors on the surface of tumor cells and was observed in mouse and human cells. When combined with chemotherapy, CTLs raised against specific antigens were able to induce apoptosis in neighboring tumor cells that did not express those antigens. These data suggest that small numbers of CTLs could mediate a potent antitumor effect when combined with chemotherapy. In addition, these results provide a strong rationale for combining these modalities for the treatment of patients with advanced cancers.


Related Papers